Page 366 - Read Online

Page 8 of 9 Nedogoda et al. Vessel Plus 2018;2:37 I http://dx.doi.org/10.20517/2574-1209.2018.36

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
The study protocol was approved by the Local Ethics Committee of the Volgograd Medical University. Each
patient was informed about the study and gave their consent.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES

1. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/
ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report
of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol
2018;71:e127-248.
2. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, et al. 2016 ESC/EAS guidelines for the management of dyslipidemias.
Eur Heart J 2016;37:2999-3058.
3. Nemcsik J, Cseprekál O, Tislér A. Measurement of arterial stiffness: a novel tool of risk stratification in hypertension. Adv Exp Med
Biol 2017;956:475-88.
4. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, et al. Prevention of cardiovascular events with an antihypertensive regimen of
amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac
Outcomes Trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
5. Manisty CH, Zambanini A, Parker KH, Davies JE, Francis DP, et al. Differences in the magnitude of wave reflection account for
differential effects of amlodipine- versus atenolol-based regimens on central blood pressure: an Anglo-Scandinavian Cardiac Outcome
Trial substudy. Hypertension 2009;54:724-30.
6. Chen X, Huang B, Liu M, Li X. Effects of different types of antihypertensive agents on arterial stiffness: a systematic review and meta-
analysis of randomized controlled trials. J Thorac Dis 2015;7:2339-47.
7. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens
2004;17:118-23.
8. Mackenzie IS, McEniery CM, Dhakam Z, Brown MJ, Cockcroft JR, et al. Comparison of the effects of antihypertensive agents on
central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009;54:409-13.
9. Elliott WJ, Childers WK. Should β blockers no longer be considered first-line therapy for the treatment of essential hypertension without
comorbidities? Curr Cardiol Rep 2011;13:507-16.
10. Hirata K, Vlachopoulos C, Adji A, O’Rourke MF. Benefits from angiotensin-converting enzyme inhibitor ‘beyond blood pressure
lowering’: beyond blood pressure or beyond the brachial artery? J Hypertens 2005;23:551-6.
11. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, et al. Cardiac hypertrophy, aortic compliance, peripheral resistance,
and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation
1994;90:2786-96.
12. Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, еt al. Atenolol and eprosartan: differential effects on central blood
pressure and aortic pulse wave velocity. Am J Hypertens 2006;19:214-9.
13. Mahmud A, Feely J. Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor
blockade in resistant hypertension. J Hum Hypertens 2000;14:541-6.
14. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, et al. Differential impact of blood pressure-lowering drugs on central aortic
pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25.
15. Boutouyrie P, Achouba A, Trunet P, Laurent S; EXPLOR Trialist Group. Amlodipine-valsartan combination decreases central systolic
blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension 2010;55:1314-22.
16. Matsui Y, Eguchi K, O’Rourke MF, Ishikawa J, Shimada K, et al. Association between aldosterone induced by antihypertensive
medication and arterial stiffness reduction: the J-CORE study. Atherosclerosis 2011;215:184-8.
17. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage
renal failure. Circulation 2001;103:987-92.
18. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.